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ABSTRACT
It is evident that the chemistry of platinum is in a more advanced state than that of gold, mainly due
to the success of the former in several anti-cancer drugs. With a view to finding possible, new
candidates with chemotherapeutic potential, the use of sulphur-donor ligands bonded to platinum
and gold is discussed herein in an attempt to promote the need to investigate similar ligands.
Chloro(2,3-diphenyl-l,3,4-thiadiazolium-5-thiolato-Sexo)gold(I) has been synthesised using a
standard reaction, whereby Au(lll) is initially reduced to Au(I) then reacted with the ligand, 2,3-
diphenyl-l,3,4-thiadiazolium-5-thiolate.hydrochloride, isolated and finally characterised by
elemental analyses and infrared spectroscopy. The compound is the first example of gold attached
to a meso-ionic compound. It has also been tested for anti-bacterial and anti-fungal activity and
shown to possess moderate activity against Gram-positive bacteria, although is inactive against
Gram-negative bacteria and fungi.
INTRODUCTION
Gold was reported as a healing agent as early as 2500 BC in the ninth province of China. Since then
the application of gold has been extended mainly due to the implementation of chrysotherapy in
the 1930’s.1a,TM Gold compounds have been employed intensively in the search for new materials
in various areas of medicinal chemistry, principally as anti-arthritics and anti-cancer drugs. Oxidation
of gold drugs in the +1 state is considered improbable although there is experimental evidence to
suggest that aurothiomalate, present in the commercialised gold sodium thiomalate (myocrisin),
could be oxidised by myeloperoxidase or by hydrogen peroxide and hypochloric acid, which are
products of burst polymorphonuclear leucocytes.2
In the period 1987-1994, most effort was directed at second-generation platinum(ll) drugs
containing diamino groups in the cis-position. Intrastrand DNA coupling was proved to be most
prevalent as it is effected principally by cis-isomers.3 On the other hand, a series of trans-platinum
anti-tumour complexes were tested in vitro and in vivo. Surprisingly, of the complexes tested in
vitro, many of them exhibited comparable potency to cisplatin whilst, in in vivo studies, all platinum
(IV) complexes tested showed significant anti-tumour activity against the subcutaneous murine
ADJ/PC 6 plasmacytoma model.4 Clearly, the chemistry of platinum(IV) has still to be further
developed.5Another interesting series of platinum(ll) complexes bonded to acyclovir (a potent,
metal-binding anti-viral drug) were synthesised and underwent biological testing. Unfortunately
though, the anti-tumour activity of the Pt-acyclovir compex cis-[PtCI(NH3)2(L)]N03, where L
acyclovir i.e. 9-(2-hydroxyethoxymethyl)guanine, was markedly less than cisplatin when
administered to P388 leukaemia-bearing mice.6 Adducts of the anti-cancer drug carboplatin with
sulphur-containing amino acids were investigated last year, as methionine and cysteine are thought
to be responsible for the inactivation of Pt(ll) complexes. The ring-opening of carboplatin and
formation of relatively stable species was proven to influence the drug’s biological activity.7
Carboplatin reacts very slowly with thiols and this may be one of the reasons why it is less toxic than
cisplatin. The bonds of any ligand to a platinum(ll) centre ought to, in theory, be sufficiently resilient
to ideally arrive at their site of action and be substituted by nitrogen bases of DNA, thus exerting
their anti-tumour activity. High solubility within the body is also essential for the drug to be absorbed
and assisted in reaching its target. Gold will react with molecules containing thiol residues present
such as glutathione (a tripeptide), metallothionein and the Cys-34 link of albumin (proteins),
amongst the many choices available, as they contain sulphhydryl groups; although the rates of
such reactions have to be studied more fully.
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GoM and Platinum with Sulphur-Donor Ligands
The in vitro and in vivo anti-mmour activity of gold complexes bound to thiolate ligands have been largely
neglected. Thiol ligands attached to gold are easily replaced, making it very doubtful that a complex will
arrive at its site of action without undergoing structural modifications. The synthesis of platinum complexes
employing novel ligands similar to biomolecules is very popular and will no doubt be extended to gold.
8a-sf
1,1-dithiolate compounds of transition metals were reviewed extensively by McCullough, although only a few
sulphur-donors, e.g. dialkyldithiocarbamates, of platinum(II) and gold(I) were described.
9 Dithiolates of
gold(l) with dianionic sulphur ligands bridging gold centres in di- and tri-nuclear complexes have also been
reported viz.; 1,2-benzene dithiolate, (1,2-S:C6H4); 1,3-benzene-dithiolate (1,3-S:C6I-h) and the 3,4-
dimercaptotoluene analogue (3,4-S_C6H3Me).
1 Metal compounds containing dithiolate ligands-as illustrated
in Figure 1 were also synthesised in the late 1980’s and although platinum and gold derivatives were cited, no
further work was performed on them.
b
When PtCI4:- is reacted with S4Nq (tetrasulphurtetranitride), complexes of platinum(II) of formula Pt(S2N:H)2
or Pt(S3N)2 containing S,N bidcntate ligands are formed. These are further examples of sulphur’s ease in
bonding to Pt, despite no mention being made to gold derivatives. Interestingly though, a product of formula
AuCI2(S3N) is obtained when STNH is deprotonated with butyl lithium and added to chloroauric acid.
l:a The
reaction in which tris(triphenylphosphine)platinum(0) forms a metallocycle is yet another example of a novel
product:
2b
Pt(PPh3)3 + S4N4H4 Pt(NSNS)(PPh3)2
Furthermore, another compound Pt(SN3)CI, which contains the SqN3 group acting as a tridentate ligand
bonding to platinum via two nitrogens and a suphur, is another fascinating example of the versatility of these
ligands.
2,2d
a) b)
Figure 1. Dithiolate ligands a) 2-thiooxo-l,3-dithiole-4,5-dithiolate and b) tetrathiosquarate
The use of bis(diphenylphosphine)methane sulphide yielded the first fully characterised gold methanide with
P,S chelation to the precious metal in the example cis-[Aum(C6Fs)2(PPh2CHPPh2S)]. Housecrofl’s review of
gold, which contains a section dedicated to sulphur-donor ligands, discusses new developments in gold(I)
chemistry, highlighting some new complexes containing Au-thiouracil, -thioether and -mercaptooxopurines.
TM
Finally, a vast number of meso-ionic compounds exist and are defined as planar five-membered heterocyclic
betaines, possessing at least one side chain whose o-atom is also in the ring plane, and have a dipole moment
of the order of 5D. To date, they have not been employed as ligands in either platinum or gold chemistry.
5 In
spite of this, the compound 1,3-diphenyl-2-(4-chloro-3-nitrophenyl)-l,3,4-triazolium-5-thiolate and its
hydrochloride were previously tested against three mttfine tumours: Ehrlich, Sarcoma 180 andB10MC11. The
hydrochloride demonstrated anti-tumour activity in vitro and good efficacy against the Ehrlich tumour
(p<0.05) when injected i.p.
16
MATERIALS AND METHODS
The meso-ionic compound, 2,3-diphenyl-l,3,4-thiadiazole-5-thiolate.hydrochloride was prepared by a
literature method.
15 All reagents were purchased from the Aldrich Chemical Company and used without
further purification, apart from NaAuCI4.2H20 which was donated by Jotmson-Matthey p.l.c.. Elemental
analyses were performed on a Perkin-Elmer 2400 microanalyser (IQ-USP). Infrared spectra were recorded on
a Bomem, Hartmann and Braun MB-Series spectrometer as potassium bromide discs in the range 4,000-400
cm-. Melting point determinations were performed on a Microquimica digital melting point apparatus, model
MQAPF-301.
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Chloro(2,3-diphenyl-1, 3,4-thiadiazolium-5-thiolato-Sa)gold(1)
Sodium tetrachloroaurate(III)(0.199 g, 0.5 retool) was dissolved in water(30 ml) in a round-bottomed
flask(100ml) and 2,2’-thiodiethanol(0.367 g, 3.0 retool) syringed in with the gradual formation of a colourless
solution of chloro(2,2’-dithioethanol)gold(I); the reaction being performed with cooling using ice under a
nitrogen atmosphere. Immediately after addition of the meso-ionic compound(0.135 g, 0.5retool) a bright
yellow colour, slightly different to the ligand itself, was imparted to the colourless solution. The reaction was
allowed to continue using magnetic agitation for 30 minutes. The product was then filtered offand redissolved
in ethanol to finally yield shiny crystals which were dried in vacuo over phosphorus pentoxide. Yield 0.151 g
(60%). F.W. 502.80. M.P. 150C (dec). Elemental analysis CI-IoN2S2AuCI: found(calculated) %(2
33.39(33.44), %H 1.82(2.01), %N 5.27(5.57). I.R. (cm-1) vo.n 3600-2800 (s); Vc--c 1594 (mw), 1490 (m),
1455 (mw); VC-N 1397 (ms), 1184 (m), 1072 (s, w); c-n in plane bending 1001 (w); -H out of plane bending
871 (m); 5c--c in plane bending of monosubstituted benzene ring 760 (s); c- out of plane bending of
monosubstituted benzene ring 682 (s); Vc.s 570 (s); VA-S447 (W); Va-Ca n.o.
Biological Testing
In the anti-bacterial testing the medium used was Oxoid’s Is-Sentitest agar, whew,as in the anti-fungal
testing Oxoid’s purified agar plus 10% yeast nitrogen base supplement was employed. A standard agar
dilution was performed to determine the minimum inhibitory concentrations (M[C’s) of the gold(I) meso-ionic
compound. Stock solutions of the test compounds were prepared in dimethylacetamide. Varying aliquots of
this or a further dilution (also dissolved in DMA) were added to a known volume of sterile media to give the
following test range of compound: 100, 25, 10, 2.5, 1.0, 0.25 xg ml
1 of afar. These were then poured into
sterile 90 mmdi’le Petri-dishes and allowed to solidify. The surface of these plates were inoculated with
suspensions of test organism containing 104 cells ml. Plates were then incubated at 37C for 24 h before
being examined for their relative growth. MIC’s were quoted as the range between the lowest concentration at
which growth was observed for a particular organism and the highest concentration at which no growth was
observed. Positive controls in each screen were ciprofloxacin (a quinolone anti-bacterial) and amphotericin B
(a polyene anti-ftmgal drug). "Before" and "after" control plates were included; these were inoculated before
and after test plates had been inoculated to ensure no interference due to carry-over of test compound. Control
plates doubled as solvent controls, which themselves can be inhibitory at certain concentrations.
RESULTS AND DISCUSSION
The reaction scheme described below is a general method for the preparation of gold(I) compounds. The
ligand employed may be a phosphine, suphide or nitrogen-donor, although the donor strength of the ligand
will vary depending upon the remainder ofthe molecule.
9
AuCLI- + tdg tdgCl2 + AuCl(tdg) + CI-
LAuCI
tdg thiodiglycol 2,2’-thiodiethanol
Figure 2. Reaction scheme for the production of complexes offormula LAuC!
A number of similar ligands containing a phenyl ring with different groups attached to them in positions 2, 3
or 4 would also produce new derivatives without interfering with the Au-S bond. The structure of chloro(1,2-
diphenyl-l,3,4-thiadiazolium-5-thiolato-So)gold(I) is represented below. Charge separation exists within the
meso-ionic moiety as a partial positive charge is centred on the carbon atom in position-2 of the betaine,
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although spreads onto adjacent atoms $1 and N3. A corresponding negative charge is located mainly on the
carbon atom in position-5 of the ring and extends towards the exocyclic sulphur atom as well as the adjacent
N atom. Hence, gold attaches readily to this sulphur atom through the one of its lone pairs, and also via the
negative charge built up around So in preference to the sulphur atom in position-1 ofthe ring.z
Ph SAuC1
Figure 3. The structure of chloro(2,3-diphenyl-l,3,4-thiadiazolium-5-thiolato-So)gold(I)
The results of biological testing against five different bacteria and four differem fungi are displayed in Tables
1 and 2.
Table 1. Anti-bacterial testing results for chloro(2,3-diphenyl-l,3,4-thiadiazolium-5-thiolato-So)gold(1)
Staphylococcus aureus 2.5 <0.25
Enterococcusfaecalis 2.5 1.0-2.5
Pseudomonas aeruginosa >100 <0.25
Escherichia coli >100 <0.25
Klebsiella pneumoniae >100 <0.25
Table 2. Anti-fungal testing results for chloro(2,3-diphenyl-l,3,4-thiadiazolium-5-thiolato-Sxo)gold(I)
Candida albicans
Cryptococcus neformans
Aspergillus niger
Aspergillusfumigatus
>100
>100
>100
>100
<0.25
<0.25
0.25-1.0
0.25-1.0
The compound, chloro(2,3-diphenyl-l,3,4-thiadiazolium-5-thiolato-Sexo)gold(I), showed reasonably good
activity against Gram-positive bacteria, although poor activity against Gram-negative bacteria was recorded;
this being a common phenomena for metal complexes. Anti-fungal test results demonstrate that the compound
is not significantly active, even though Cryptococcus neoformans is generally sensitive to metal compounds.
As a final consideration, many gold meso-ionic compounds including substituted 1,3,4-triazolium-5-thiolates
or 1,3,4-oxadiazolium-2-thiolates can be oxidised via halogens to their corresponding gold(III) derivatives
and, thereupon, reacted with ligands which facilitate substitution of these groups. Ligands such as the silver
salts of the anions displayed in Figure 1 will form part of our future investigations. Additionally, it is
conceivable that gold(I) meso-ionic derivatives could react through substitutents in their aromatic ring systems
and, for example, form poly-nuclear gold compounds.
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